The Critical Layer for Pharma's Growing Direct-to-Patient Play
Published: | Updated:
DTP programs are outpacing regulatory guidance. Chander Viswanathan and Shannon Wiley, JD, make the case for compliance-by-design infrastructure over reactive fixes.
